Pablo Mozas, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, comments on the improving treatment landscape for patients with chronic lymphocytic leukemia (CLL), emphasizing the value of agents including BTK inhibitors and BCL-2 inhibitors. Dr Mozas then goes on to discuss the promising results observed with the use of zanubrutinib, highlighting findings from the SEQUOIA trial (NCT03336333). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.